What's Happening?
Innovent Biologics, a biopharmaceutical company, has announced promising results from a Phase 1 proof-of-concept clinical study of its PD-1/IL-2α-bias bispecific fusion protein, IBI363, in treating advanced immunotherapy-resistant non-small cell lung
cancer (NSCLC). The study, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, involved 136 subjects with NSCLC. The results showed that IBI363 monotherapy demonstrated strong overall survival benefits, particularly in patients with squamous NSCLC and adenoNSCLC. The study highlighted a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months in the 3 mg/kg dose group for squamous NSCLC patients. Additionally, the treatment showed a favorable safety profile with manageable adverse events.
Why It's Important?
The findings from Innovent's study are significant as they address a critical unmet need in the treatment of NSCLC, particularly for patients who have not responded to existing immunotherapies. The robust survival benefits and favorable safety profile of IBI363 suggest it could become a viable treatment option for patients with limited alternatives. This development could potentially improve survival rates and quality of life for patients with immunotherapy-resistant NSCLC, a group that currently faces limited treatment options. The study's results also underscore the potential of bispecific fusion proteins in oncology, offering a new avenue for cancer treatment.
What's Next?
Following the promising results, IBI363 has entered a global Phase 3 clinical study for immunotherapy-resistant squamous NSCLC. Innovent, in collaboration with Takeda, plans to initiate a global Phase 3 study for non-squamous NSCLC as well. These studies will further evaluate the efficacy and safety of IBI363, potentially leading to regulatory approval and commercialization. The continued development of IBI363 could pave the way for its use in broader patient populations and additional cancer types, pending successful trial outcomes.
